Rana R. McKay, MD, University of California, San Diego

Metastatic CRPC: Novel Treatment Strategies With Radioligand Therapy

August 15th 2023

Key opinion leaders share insight to novel combination strategies and clinical trials focused on radioligand therapy in metastatic castration-resistant prostate cancer.

Radioligands in the Treatment of Metastatic CRPC: Radium-223

August 15th 2023

Continuing their segment on radioligand therapy in metastatic castration-resistant prostate cancer, panelists highlight data behind use of radium-223.

Radioligands in the Treatment of Metastatic CRPC: Lutetium-177–PSMA-617

August 8th 2023

Focused discussion on the role of lutetium-177–PSMA-617 as radioligand therapy in patients with metastatic castration-resistant prostate cancer.

Combination PARPi Strategies in Metastatic CRPC: Interpreting Data From Clinical Trials

August 8th 2023

Key opinion leaders in metastatic castration-resistant prostate cancer management review a subset of clinical trials focused on combination strategies with PARP inhibitors.

Advent of PARP Inhibitors in Metastatic CRPC

August 1st 2023

Moving on to discuss metastatic castration-resistant prostate cancer, panelists highlight the evolving role of PARP inhibition in this setting.

Evolving Treatment Landscape of Nonmetastatic Castration-Resistant Prostate Cancer

August 1st 2023

Comprehensive insight to key treatment modalities for patients with nonmetastatic castration-resistant prostate cancer and how to select amongst them.

Informing Systemic Therapy Selection With Negative Data in HSPC

July 25th 2023

A brief conversation on negative clinical trial readouts and how they may help to inform optimal treatment pathways for patients with metastatic hormone-sensitive prostate cancer.

What is the Role of Locoregional Therapy in Metastatic HSPC?

July 25th 2023

Following their discussion on systemic therapy, expert panelists consider the value of locoregional therapy for a subset of patients with metastatic hormone-sensitive prostate cancer.

Dr. McKay on the Rationale for Triplet Frontline Therapy in RCC

November 22nd 2022

Rana R. McKay, MD, discusses the pros and cons of utilizing triplet therapy in the frontline treatment of patients with renal cell carcinoma.

Dr. McKay on Recent Advancements in the Frontline Treatment of Metastatic RCC

November 4th 2022

Rana R. McKay, MD, discusses four key trials that have advanced the frontline treatment of metastatic renal cell carcinoma in the modern era.

Dr. McKay on the Outcomes of Landmark Trials in Frontline RCC

October 11th 2021

Rana R. McKay, MD, discusses the outcomes of landmark clinical trials in frontline renal cell carcinoma.

Final Thoughts on the Management of mRCC

October 23rd 2020

Additional Emerging Therapies for Progressive mRCC

October 23rd 2020

Emerging Agents for Progressive mRCC

October 23rd 2020

Sequencing After Frontline I/O Based Regimen for mRCC

October 23rd 2020

Clinical Trials for Relapsed/Refractory mRCC

October 23rd 2020

Upcoming Combination Trials for mRCC

October 23rd 2020

I/O Therapy After Progression on I/O for mRCC

October 23rd 2020

Role of TKI After Progression on I/O for mRCC

October 23rd 2020

Review of the COSMIC 021 Study for mRCC

October 23rd 2020